Kann CSL Alzheimer behandeln ? - 500 Beiträge pro Seite

[Oberkassel]

CSL Australisches Biopharma Unternehmen verdienst mit Biopharmazeutika gutes Geld.

http://www.csl.com.au/about

Kurs: 54,77 AUS
Stop Loss 46,50 AUS


Vor allem für Fantasie sorgt die Aussicht auf potentielle Wirkstoffe zur Behandlung der Alzheimer Krankheit.
Bislang sind alle Versuche der weltweiten Pharmaindustrie fehlgeschlagen, Mittel zu entwickeln, die die Krankheit selbst behandeln und nicht nur die Begleitumstände zu lindern.

Die ersten Studienergebnisse sind ermutigend, das sich CSL ein Stück von dem Kuchen abschneidet. Einzuschränken ist ob diese Phantasie schon im Aktienkurs eingepreist ist. Die Prognosen des laufenden Geschäftsjahrs wurden erhöht. Ich denke es bleibt ein spekulatives Investment.

Charttechnik: Quelle:Cortal Consors

Unser Pivot-Punkt liegt bei 49.8.
Unsere Meinung: solange die Unterstützung bei 49.8 hält, ist die Aufwärtstendenz intakt.
Alternatives Szenario: ein Fall unter 49.8 würde einen weiteren Rückgang auf 46.3 auslösen
Analyse: der RSI liegt über 70. Das kann bedeuten, dass sich die Aktie entweder in einem anhaltenden Aufwärtstrend befindet oder dass sie überkauft ist und deshalb korrigieren wird (in diesem Fall auf bearishe Divergenzen achten). Der MACD liegt über der Signallinie und ist positiv. Die Konfiguration ist positiv. Es wird darauf hingewiesen, dass die Volumina seit einigen Tagen ansteigen.

Neben CSl ist der Konzern Baxter ein weiterer zukünftiger Kandidat auf dem Gebiet zur Bekämpfung der Alzheimer Krankheit hat aber einen zeitlichen Rückstand gegenüber CSL.

Frage:

Wer hat diesen Wert schon in seinem Depot und hat längerfristige Erfahrungen zu diesem Wert?

An welchen Börsenplätzen handelt Ihr den Wert ? ASX, Europa Frankfurt?

Danke im voraus für die Unterstützung !

Würde mir eine anregende Diskussion wünschen.

Schönen zweiten Advent.

Oberkassler

[Oberkassel]

!

Dieser Beitrag wurde von CloudMOD moderiert. Grund: auf eigenen Wunsch des Users

[Oberkassel]

CSL's healthy glow outshines market as top investment

VACCINE maker CSL has been rated the best-performing company by Australia's top fund managers and equity analysts.

The biotech firm, which has posted market gains of more than 70 per cent this year, has been the most sought after stock for investors, according to the latest annual East Coles survey of fund managers.

CSL performed strongly across more than two dozen categories that sharemarket professionals look for to help them make a decision about investing in a company. It also emerged with the top spot overall for best company and its chief executive Brian McNamee was rated at the best chief executive.

CSL's chief financial officer, Gordon Naylor, said the results reflected the company's long-term approach. ''The organisation is pretty focused on what it does, and has been over a long period of time,'' Mr Naylor said on Friday.

''At the end of the day, you need to understand what you do,'' he said.

CSL, which was privatised by the Commonwealth government more than two decades ago, has maintained its focus on patients even as its footprint moved from the local market to global, Mr Naylor said.

''That ethos of technical excellence is still there. We understand the importance of our medicines for our patients. These are life-saving medicines, they're not discretionary products.''

In terms of shareholder returns over the past year, CSL ranks among market leaders. Even faced with production in two of the highest currency economies of Australia and Switzerland, CSL reported its first $US1 billion profit, on $US4.6 billion of revenue. CSL is now capitalised at $27 billion. Its shares easily outperformed the S&P/ASX 200 Index, which is up 14.2 per cent over the same period.

But any success on the share market has been largely incidental, Mr Naylor said. ''We very actively manage the economics of the company, but we don't rush around to get quarterly results,'' he said.

The East Coles survey, published exclusively in BusinessDay, is based on interviews with analysts across the nation's biggest institutional brokerages and some of the largest fund managers, which collectively oversee equity investments running into hundreds of billions of dollars. The interviews took place over the past two months.

It covers 21 categories, including shareholder value, risk management, investor relations. Coca Cola Amatil's board, led by David Gonksi, took the top spot for most effective board.

Commonwealth Bank was the only banking stock to make the finalist of best companies and its chief executive Ian Narev emerged as the only bank boss to make the top 10.

Even so, the dominance of the health care sector among top overall companies is notable given their relatively small size compared to resources and financial stocks. Among the strong health performers was bionic ear manufacturer Cochlear in tenth spot. Packaging group Amcor also polled highly across several categories, marking a substantial turnaround from mid-last decade when it was shunned by investors.

Still, banks rated highly across several categories, including best chief financial officer with Westpac veteran Phil Coffey taking the top spot. Other areas where banks dominated were best investor relations (Westpac) and best investor briefings (ANZ).

The big resource houses were notably absent, although BHP Billiton emerged with the best website.

However, junior gold miner Regis Resources rated in the top three across several categories, including best disclosure, top shareholder focus and clearest strategy.

Other top performers among chief executives include Greg Kilmister, of commercial laboratory specialist ALS, who was ranked second and third-ranked Robert Velletri of Monadelphous.

Other top chief executives were Terry Davis, of Coca-Cola Amatil, and Ramsay Health Care's Chris Rex, who were ranked fourth and fifth respectively.


http://www.theage.com.au/business/csls-healthy-glow-outshine…

Ist auf meiner Watchlist.

Oberkassler